

Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting).

Open: 1:00 p.m. to 4:00 p.m.

Agenda: Report of Division Director and Division Staff.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Kelly Y. Poe, Ph.D., Acting Director, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F50, Bethesda, MD 20892, 301-496-7291, poeky@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice at least 10 days in advance of the meeting. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <https://www.niaid.nih.gov/about/advisory-council>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: December 19, 2022.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-27955 Filed 12-22-22; 8:45 am]

BILLING CODE 4140-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Submission for OMB Review; 30-Day Comment Request: National Institute on Drug Abuse (NIDA) Summer Research Internship Program**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Wilson Compton, Acting Director, Office of Research Training, Diversity and Disparities, 3WPN, 11601 Landsdown St., Room 09D18, North Bethesda, Maryland, 20892 or call non-toll-free number (301) 443-6480 or Email your request, including your address, to: [Wilson.Compton@nih.gov](mailto:Wilson.Compton@nih.gov).

**SUPPLEMENTARY INFORMATION:** This proposed information collection was previously published in the **Federal Register** on October 21, 2022, page 64068 (87 FR 64068) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment.

The National Institute on Drug Abuse (NIDA), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it

displays a currently valid OMB control number.

In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

*Proposed Collection:* National Institute on Drug Abuse (NIDA) Summer Research Internship Program—0925-0738—expiration date, 12/31/2022, EXTENSION, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH).

*Need and Use of Information Collection:* The purpose of the proposed information is for the selection of interns for the continuing NIDA Summer Research Internship Program. This request is to allow NIDA to collect information from applicants in order to meet the goals of the program and IC mission. Applicant eligibility for this program is open to those 18 and over in the year of application per NIH policy document 2022 Summer Research Internship Program (NIDA-SRIP) Policy. NIDA will request clearance for any additional forms should new programs be introduced in the future.

The information ensures that students applying to this program meet basic eligibility requirements; indicates their interest in substance abuse research, future career goals, and, if selected for the program, what research they prefer to conduct. The information also enables decision-making regarding which applicants will be selected for internships. In each case, completing the application is voluntary, but in order to receive due consideration, the prospective applicant must complete all fields required by the program.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 300.

**ESTIMATED ANNUALIZED BURDEN HOURS**

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hour
Summer Internship .....	Individuals—household .....	300	1	1	300
Total .....	.....	.....	300	.....	300

Dated: December 20, 2022.

**Lanette A. Palmquist,**

*Project Clearance Liaison, National Institute on Drug Abuse, National Institutes of Health.*

[FR Doc. 2022-27990 Filed 12-22-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and Other Cargoes for HIV and SUD Mechanistic or Therapeutic Research.

*Date:* January 25, 2023.

*Time:* 1:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Caitlin Elizabeth Angela Moyer, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-4577 [caitlin.moyer@nih.gov](mailto:caitlin.moyer@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: December 19, 2022.

**Tyeshia M. Roberson-Curtis,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022-27956 Filed 12-22-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Request for comments on the initial revised draft of the Update to the Certified Community Behavioral Health Clinics certification criteria

**AGENCY:** Substance Abuse and Mental Health Services Administration.

**ACTION:** Request for Comments on the Initial Revised Draft of the Update to the Certified Community Behavioral Health Clinics Certification Criteria.

SAMHSA is seeking public comment on the initial revised draft of the update to the Certification Criteria for Certified Community Behavioral Health Clinics (CCBHCs). CCBHCs were established under the Section 223 of the Protecting Access to Medicare Act of 2014 (PAMA, Pub. L. 113-93). Section 223 of PAMA requires the establishment of Medicaid demonstration programs to improve community behavioral health services through the development of CCBHCs. CCBHCs are required to provide a comprehensive array of coordinated services to anyone who requests care for mental health or substance use, regardless of ability to pay, place of residence, or age—including developmentally appropriate care for children. PAMA required the Department of Health and Human Services (HHS) to develop criteria for states to use when certifying clinics to participate in their demonstration programs. These criteria include six areas: (1) staffing, (2) availability and accessibility of services, (3) care coordination, (4) scope of services, (5) quality and other reporting, and (6) organizational authority. The current Certification Criteria can be found at: [https://www.samhsa.gov/sites/default/files/programs\\_campaigns/ccbhccriteria.pdf](https://www.samhsa.gov/sites/default/files/programs_campaigns/ccbhccriteria.pdf).

There have been significant developments in the CCBHC program and in the broader mental health and substance use disorder field since the development of the existing Certification Criteria. States and

providers now have six years of experience with the CCBHC model and lessons learned related to the implementation of the Certification Criteria. SAMHSA is seeking to make minor revisions to the Criteria to respond to these developments and lessons learned, while still maintaining the overarching requirements for program areas and scope of services outlined in PAMA.

To develop the initial draft of the updated CCBHC Criteria, SAMHSA gathered input in several ways. Public opportunities for input were posted on <https://www.samhsa.gov/certified-community-behavioral-health-clinics/ccbhccriteria-update-announcements>. Public meeting dates and virtual locations were disseminated through SAMHSA listservs. On November 17, 2022, SAMHSA held a virtual public listening session open to the public to provide input on the existing CCBHC Criteria. SAMHSA also accepted written input from the public and stakeholders sent to [ccbhccriteria@samhsa.hhs.gov](mailto:ccbhccriteria@samhsa.hhs.gov) by November 21, 2022. In addition to public outreach, SAMHSA also received feedback on potential revisions to the existing CCBHC Criteria from key stakeholders and federal partners.

The initial draft of the updated CCBHC Criteria will be available for public comment before the end of December 2022 and will be open to mid-January 2023. Information on CCBHC Criteria updates and the process to support them is available at: <https://www.samhsa.gov/certified-community-behavioral-health-clinics/ccbhccriteria-update-announcements>. The posting of the initial draft of the updated CCBHC Criteria will also be announced through SAMHSA's listserv, CCBHC Training and Technical Assistance grant program, and CCBHC State Technical Assistance contract. SAMHSA requests all comments to the initial draft of the updated CCBHC Criteria be sent to [ccbhccriteria@samhsa.hhs.gov](mailto:ccbhccriteria@samhsa.hhs.gov).

*Authority:* Section 223 of the Protecting Access to Medicare Act (2014), as amended.

*Contact:* Mary Blake, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, telephone (240) 276-1747; email: [mary.blake@samhsa.hhs.gov](mailto:mary.blake@samhsa.hhs.gov).

**Alicia Broadus,**

*Public Health Advisor.*

[FR Doc. 2022-28028 Filed 12-22-22; 8:45 am]

**BILLING CODE 4162-20-P**